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INVITED COMMENTARY
Richard P. Cambria, MD, Boston, Mass
Stent-graft repair of thoracic aortic pathology has proceeded
at a frustrating pace on the North American side of the Atlantic.
The engineering, regulatory, and commercial interest issues re-
sponsible for this slow (compared with abdominal aortic aneu-
rysm) development have been the subject of considerable discus-
sion among the involved parties. At the present time, except for a
very few centers holding physician-sponsored Investigational De-
vice Exemptions, this technology is only available in the United
States in the form of 3 Phase II clinical trials, which are currently
restricted to treatment of degenerative thoracic aneurysms (DTA)
in candidates for open surgery. Furthermore, given the “morbidity
quotient” of conventional surgery for thoracic aortic (TA) pathol-
ogy, the clinical need for stent-graft repair in this area is both
obvious and pressing. The good news is that the latter is now
recognized by all parties involved and, with the imminent publica-
tion of the first US pivitol trial,1 there likely will be a commercially
available graft in the United States within a year.
The present Eurostar/United Kingdom registry report is cer-
tainly the largest compendium of patients treated with thoracic
aortic stent grafts. Readers of the Journal of Vascular Surgery are
accustomed to valuable clinical reports from the Eurostar registry,
and the present study will certainly serve (at least temporarily) as a
benchmark for periprocedural results achievable with TA stent
grafts. Procedural mortality was in line with the available literature,
particularly since many patients treated with TA stent grafts are in
genuinely desperate clinical circumstances. Emergency treatment
was required in half the dissection patients and in 25% of those with
DTA. The authors’ results with respect to central nervous system
complications are admirable. Stroke has been a vexing problem in
this arena, and I concur with their sanguine discussion concerning
the low—but not zero—risk of spinal cord ischemia.
Limitations of this study are many and a function of the registry
format. This report is a cataloguing of procedures performed and,
accordingly, cannot address the important issues of patient clinical and
anatomic selection criteria. We know little or nothing of the indica-
tions for treatment, relative experience and expertise with open sur-
gery at the 62 contributing institutions, nor even the vigor of these
data. Fewer than 50% of patients had 1-year follow-up data available.
According to the data that were available, a disturbing 15% of DTA
patients experienced aneurysm expansion (although not defined)
despite low rates of endoleak and a zero graft-migration rate! Al-
though aneurysm-related death was rare, these data are in need of
clarification as more follow-up data become available.
As for the different pathologies treated, in the TA the spec-
trum is wide, from focal lesions (eg, traumatic tear, anastomotic
false aneurysm, penetrating ulcer) for which TA stent-graft repair
seems ideal, to complex clinical/anatomic circumstances (eg, Type
III B dissections) wherein definitive data can be generated only by
well-designed clinical trials. The authors record treatment of 50
cases of traumatic aortic tear with excellent overall results. Given
the incidence of this injury, this is a large number of cases, and
readers of JVS will soon be availed of other reports detailing similar
results with stent-graft repair of traumatic aortic tear. Despite the
general need of US endovascular surgeons to apply abdominal
aortic “cuffs” in an off-label application to repair traumatic tears, it
seems evident that the TA stent graft will soon be the treatment of
choice for this lesion. Such can hardly be considered the case in the
complexities of type B aortic dissection. Although the authors
treated some 130 cases, the indications for treatment and the
clinical circumstances thereof are vague and debatable, and the
desired detail in this regard is likely not retrievable from the registry
format. In type B dissection, stent-graft repair at the aortic entry
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tear can, in theory, be used to treat both acute (eg, threatened
rupture, malperfusion syndrome) and late (eg, chronic aneurysm
formation) complications of the disease. In the present report, half
the cases were treated electively, yet 2-thirds of these were reported
as symptomatic—many with persistent back pain or threatened
rupture. The latter is, in fact, uncommon with modest-sized aortae
in Type B dissection and the significance of “continued back pain”
is ephemeral.2 In the 22 cases treated for side-branch occlusion,
the authors inform us that no adjunctive peripheral endovascular
procedures (fenestrations, branch stenting) were required. Expe-
rience elsewhere would suggest that such adjunctive procedures
are often required to effectively treat malperfusion syndrome.3
Perhaps all of the authors’ patients serendipitously had dynamic
side-branch obstruction (wherein re-expansion of the true lumen
could be anticipated to effectively treat malperfusion), or some of
the adjunctive surgical procedures which the registry is unable to
further detail, were directed at peripheral vascular complications of
the dissections.4 I would chide the authors a bit in their notation of
a “94% satisfactory CT scan appearance” at 1 year in the dissection
cases (n 63). Since the mean diameter of the dissected aortae was
but 46 mm, and the authors did not require total elimination of
false lumen flow as a criterion for anatomic success, the figure for
favorable computed tomography scan data could be predicted.
This is not so much a criticism as it is an assertion of the complex-
ities of stent grafting in aortic dissections. The need for well-
designed clinical trials is evident; the European INSTEAD trial,
related to its design (patients randomized to stent graft versus
medical therapy after the acute phase of the disease) will address
only the issue of chronic aneurysm formation.
These are exciting times for vascular and endovascular sur-
geons whose practices encompass thoracic aortic pathology. This
reviewer would strongly encourage vascular surgeons to be expert
in the cognitive and judgmental aspects of treating TA pathology,
as endovascular skills ideally position us to offer such patients
innovative minimally invasive options. The Eurostar/U.K. registry
participants are to be congratulated for their efforts at rapidly
accumulating and collating experience in a field where substantial
experience can be achieved only with multicenter cooperative
effort. We anticipated future follow-up studies from these registries
with great interest.
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